Drug updated on 11/15/2023
| Dosage Form | Capsule (oral: 40 mg, 80 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
- For the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
- For the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
- For the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Retevmo (selpercatinib) Prescribing Information. | 2021 | Lilly USA, LLC, Indianapolis, IN |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical, pharmacoeconomic, and stakeholder input combined report. | 2023 | CADTH |
| Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: | 2023 | Cancer investigation |
| Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. | 2022 | NICE |
| Clinical and pharmacoeconomic combined report. | 2022 | CADTH |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Therapy for stage iv non–small-cell lung cancer with driver alterations: ASCO living guideline. | 2022 | Journal of Clinical Oncology |
| NCCN guidelines insights: non–small cell lung cancer, version 2.2021. | 2021 | Journal of the National Comprehensive Cancer Network |